Mechanisms of fingolimod's efficacy and adverse effects in multiple sclerosis (Q33881977)

29 July 2017

1 reference

title

Mechanisms of fingolimod's efficacy and adverse effects in multiple sclerosis (English)

1 reference

29 July 2017

0 references

Jerold Chun

2

1 reference

29 July 2017

Jeffrey A. Cohen

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A21520239

30 November 2024

language of work or name

English

1 reference

National Center for Biotechnology Information

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/esummary.fcgi?db=pubmed&retmode=json&id=21520239

30 November 2024

publication date

1 May 2011

1 reference

29 July 2017

May 2011

1 reference

National Center for Biotechnology Information

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/esummary.fcgi?db=pubmed&retmode=json&id=21520239

full work available at URL

30 November 2024

https://api.wiley.com/onlinelibrary/tdm/v1/articles/10.1002%2Fana.22426

1 reference

https://onlinelibrary.wiley.com/doi/pdf/10.1002/ana.22426

30 November 2024

1 reference

30 November 2024

1 reference

29 July 2017

volume

69

1 reference

29 July 2017

issue

5

1 reference

29 July 2017

page(s)

759-777

1 reference

Multiple sclerosis--the plaque and its pathogenesis

29 July 2017

cites work

1 reference

Premyelinating oligodendrocytes in chronic lesions of multiple sclerosis

21 January 2018

1 reference

Remyelination is extensive in a subset of multiple sclerosis patients.

21 January 2018

1 reference

Neuroprotection and neuroregeneration in multiple sclerosis

21 January 2018

1 reference

Distribution of lymphocyte subsets and natural killer cells in the human body

21 January 2018

1 reference

Central memory and effector memory T cell subsets: function, generation, and maintenance

21 January 2018

1 reference

Sphingosine-1-phosphate: an enigmatic signalling lipid

21 January 2018

1 reference

Generation and metabolism of bioactive sphingosine-1-phosphate

21 January 2018

1 reference

Enzymatic measurement of sphingosine 1-phosphate

21 January 2018

1 reference

Lysophospholipid receptors

21 January 2018

1 reference

Signaling and biological actions of sphingosine 1-phosphate

21 January 2018

1 reference

Lysophospholipid receptors: signaling and biology

21 January 2018

1 reference

International Union of Basic and Clinical Pharmacology. LXXVIII. Lysophospholipid receptor nomenclature

21 January 2018

1 reference

Activation-regulated expression and chemotactic function of sphingosine 1-phosphate receptors in mouse splenic T cells

21 January 2018

1 reference

Cyclical modulation of sphingosine-1-phosphate receptor 1 surface expression during lymphocyte recirculation and relationship to lymphoid organ transit

21 January 2018

1 reference

Lymphocyte sequestration through S1P lyase inhibition and disruption of S1P gradients

21 January 2018

1 reference

Linking Chinese medicine and G-protein-coupled receptors

21 January 2018

1 reference

Single-dose FTY720 pharmacokinetics, food effect, and pharmacological responses in healthy subjects

21 January 2018

1 reference

Pharmacodynamics of single doses of the novel immunosuppressant FTY720 in stable renal transplant patients.

21 January 2018

1 reference

Pharmacodynamics, pharmacokinetics, and safety of multiple doses of FTY720 in stable renal transplant patients: a multicenter, randomized, placebo-controlled, phase I study

21 January 2018

1 reference

Multiple-dose FTY720: tolerability, pharmacokinetics, and lymphocyte responses in healthy subjects

21 January 2018

1 reference

FTY720, a novel immunomodulator in de novo kidney transplant patients: pharmacokinetics and exposure-response relationship

21 January 2018

1 reference

Physiologically based pharmacokinetic modeling of FTY720 (2-amino-2[2-(-4-octylphenyl)ethyl]propane-1,3-diol hydrochloride) in rats after oral and intravenous doses.

21 January 2018

1 reference

Brain penetration of the oral immunomodulatory drug FTY720 and its phosphorylation in the central nervous system during experimental autoimmune encephalomyelitis: consequences for mode of action in multiple sclerosis

21 January 2018

1 reference

The immune modulator FTY720 targets sphingosine 1-phosphate receptors

21 January 2018

1 reference

Alteration of lymphocyte trafficking by sphingosine-1-phosphate receptor agonists

21 January 2018

1 reference

Phosphorylation of the immunomodulatory drug FTY720 by sphingosine kinases

21 January 2018

1 reference

The immunosuppressant FTY720 is phosphorylated by sphingosine kinase type 2

21 January 2018

1 reference

Mice deficient in sphingosine kinase 1 are rendered lymphopenic by FTY720.

21 January 2018

1 reference

Sphingosine kinase 2 is required for modulation of lymphocyte traffic by FTY720

21 January 2018

1 reference

Sphingosine kinase type 2 is essential for lymphopenia induced by the immunomodulatory drug FTY720.

21 January 2018

1 reference

Immunosuppressive and anti-angiogenic sphingosine 1-phosphate receptor-1 agonists induce ubiquitinylation and proteasomal degradation of the receptor

21 January 2018

1 reference

Persistent signaling induced by FTY720-phosphate is mediated by internalized S1P1 receptors.

21 January 2018

1 reference

Lymphocyte egress from thymus and peripheral lymphoid organs is dependent on S1P receptor 1

21 January 2018

1 reference

Sphingosine 1-phosphate (S1P) receptor subtypes S1P1 and S1P3, respectively, regulate lymphocyte recirculation and heart rate

21 January 2018

1 reference

Oral fingolimod (FTY720) for relapsing multiple sclerosis

21 January 2018

1 reference

A placebo-controlled trial of oral fingolimod in relapsing multiple sclerosis

21 January 2018

1 reference

Oral fingolimod or intramuscular interferon for relapsing multiple sclerosis

21 January 2018

1 reference

Rate of brain atrophy in relapsing MS decreases during treatment with IFNbeta-1a.

21 January 2018

1 reference

MRI outcomes in a placebo-controlled trial of natalizumab in relapsing MS.

21 January 2018

1 reference

FTY720, a novel immunomodulator: efficacy and safety results from the first phase 2A study in de novo renal transplantation

21 January 2018

1 reference

Pharmacokinetic/pharmacodynamic relationships of FTY720 in kidney transplant recipients

21 January 2018

1 reference

Reconstitution of circulating lymphocyte counts in FTY720-treated MS patients

21 January 2018

1 reference

FTY720 exerts differential effects on CD4+ and CD8+ T-lymphocyte subpopulations expressing chemokine and adhesion receptors.

21 January 2018

1 reference

Th17 central memory T cells are reduced by FTY720 in patients with multiple sclerosis

21 January 2018

1 reference

T helper type 1 and 17 cells determine efficacy of interferon-beta in multiple sclerosis and experimental encephalomyelitis

21 January 2018

1 reference

FTY720 therapy exerts differential effects on T cell subsets in multiple sclerosis.

21 January 2018

1 reference

FTY720 (fingolimod) in Multiple Sclerosis: therapeutic effects in the immune and the central nervous system

21 January 2018

1 reference

Plasma cell S1P1 expression determines secondary lymphoid organ retention versus bone marrow tropism

21 January 2018

1 reference

FTY720 alters lymphocyte homing and protects allografts without inducing general immunosuppression

21 January 2018

1 reference

Sphingosine-1-phosphate receptor agonism impairs the efficiency of the local immune response by altering trafficking of naive and antigen-activated CD4+ T cells

21 January 2018

1 reference

Essential role for sphingosine kinases in neural and vascular development

21 January 2018

1 reference

Sphingosine kinase 1/S1P receptor signaling axis controls glial proliferation in mice with Sandhoff disease.

21 January 2018

1 reference

Essential roles of sphingosine 1-phosphate/S1P1 receptor axis in the migration of neural stem cells toward a site of spinal cord injury.

21 January 2018

1 reference

Extracellular release of newly synthesized sphingosine-1-phosphate by cerebellar granule cells and astrocytes

21 January 2018

1 reference

Sphingosine-1-phosphate is released by cerebellar astrocytes in response to bFGF and induces astrocyte proliferation through Gi-protein-coupled receptors.

21 January 2018

1 reference

FTY720 (fingolimod) efficacy in an animal model of multiple sclerosis requires astrocyte sphingosine 1-phosphate receptor 1 (S1P1) modulation

21 January 2018

1 reference

Astrocytes--friends or foes in multiple sclerosis?

21 January 2018

1 reference

Astrocytes in multiple sclerosis: a product of their environment

21 January 2018

1 reference

Antiproliferative properties of sphingosine-1-phosphate in human hepatic myofibroblasts

21 January 2018

1 reference

Assessment of the role of sphingosine 1-phosphate and its receptors in high-density lipoprotein-induced stimulation of astroglial cell function

21 January 2018

1 reference

Common signaling pathways link activation of murine PAR-1, LPA, and S1P receptors to proliferation of astrocytes.

21 January 2018

1 reference

Pharmacological characterization of lysophospholipid receptor signal transduction pathways in rat cerebrocortical astrocytes.

21 January 2018

1 reference

Growth factor pre-treatment differentially regulates phosphoinositide turnover downstream of lysophospholipid receptor and metabotropic glutamate receptors in cultured rat cerebrocortical astrocytes

21 January 2018

1 reference

Phosphorylated FTY720 promotes astrocyte migration through sphingosine-1-phosphate receptors

21 January 2018

1 reference

Sphingosine 1-phosphate induces expression of early growth response-1 and fibroblast growth factor-2 through mechanism involving extracellular signal-regulated kinase in astroglial cells.

21 January 2018

1 reference

Basic fibroblast growth factor-induced proliferation of primary astrocytes. evidence for the involvement of sphingomyelin biosynthesis

21 January 2018

1 reference

Molecular cloning, tissue-specific expression, and chromosomal localization of a novel nerve growth factor-regulated G-protein- coupled receptor, nrg-1.

21 January 2018

1 reference

Characterization of a novel sphingosine 1-phosphate receptor, Edg-8

21 January 2018

1 reference

Brain sphingosine-1-phosphate receptors: implication for FTY720 in the treatment of multiple sclerosis

21 January 2018

1 reference

Edg-8 receptors are preferentially expressed in oligodendrocyte lineage cells of the rat CNS

21 January 2018

1 reference

Edg8/S1P5: an oligodendroglial receptor with dual function on process retraction and cell survival.

21 January 2018

1 reference

Characterization of lysophosphatidic acid and sphingosine-1-phosphate-mediated signal transduction in rat cortical oligodendrocytes

21 January 2018

1 reference

Functional consequences of S1P receptor modulation in rat oligodendroglial lineage cells.

21 January 2018

1 reference

Activation of sphingosine-1-phosphate receptor S1P5 inhibits oligodendrocyte progenitor migration.

21 January 2018

1 reference

Cyclical and dose-dependent responses of adult human mature oligodendrocytes to fingolimod.

21 January 2018

1 reference

FTY720 modulates human oligodendrocyte progenitor process extension and survival.

21 January 2018

1 reference

Central nervous system-directed effects of FTY720 (fingolimod).

21 January 2018

1 reference

The immunomodulator FTY720 has a direct cytoprotective effect in oligodendrocyte progenitors

21 January 2018

1 reference

The roles of ceramide and complex sphingolipids in neuronal cell function

21 January 2018

1 reference

Embryonic brain expression analysis of lysophospholipid receptor genes suggests roles for s1p(1) in neurogenesis and s1p(1-3) in angiogenesis

21 January 2018

1 reference

Sphingosine 1-phosphate-induced cell rounding and neurite retraction are mediated by the G protein-coupled receptor H218

21 January 2018

1 reference

Nerve growth factor survival signaling in cultured hippocampal neurons is mediated through TrkA and requires the common neurotrophin receptor P75.

21 January 2018

1 reference

Involvement of sphingosine-1-phosphate in glutamate secretion in hippocampal neurons

21 January 2018

1 reference

FTY720 ameliorates MOG-induced experimental autoimmune encephalomyelitis by suppressing both cellular and humoral immune responses

21 January 2018

1 reference

Sphingosine 1-phosphate receptor agonists attenuate relapsing-remitting experimental autoimmune encephalitis in SJL mice.

21 January 2018

1 reference

FTY720 attenuates accumulation of EMAP-II+ and MHC-II+ monocytes in early lesions of rat traumatic brain injury

21 January 2018

1 reference

Treatment with immunosuppressants FTY720 and tacrolimus promotes functional recovery after spinal cord injury in rats

21 January 2018

1 reference

Sphingosine-1-phosphate signaling in the cardiovascular system

21 January 2018

1 reference

Cell type-specific localization of human cardiac S1P receptors

21 January 2018

1 reference

Sphingosylphosphocholine is a naturally occurring lipid mediator in blood plasma: a possible role in regulating cardiac function via sphingolipid receptors

21 January 2018

1 reference

The heart rate decrease caused by acute FTY720 administration is mediated by the G protein-gated potassium channel I.

21 January 2018

1 reference

Immune cell regulation and cardiovascular effects of sphingosine 1-phosphate receptor agonists in rodents are mediated via distinct receptor subtypes.

21 January 2018

1 reference

Edg-1, the G protein-coupled receptor for sphingosine-1-phosphate, is essential for vascular maturation

21 January 2018

1 reference

Constitutive expression of the S1P1 receptor in adult tissues.

21 January 2018

1 reference

Sphingosine-1-phosphate agonists increase macrophage homing, lymphocyte contacts, and endothelial junctional complex formation in murine lymph nodes

21 January 2018

1 reference

FTY720: sphingosine 1-phosphate receptor-1 in the control of lymphocyte egress and endothelial barrier function.

21 January 2018

1 reference

Endothelial cell barrier regulation by sphingosine 1-phosphate

21 January 2018

1 reference

Pulmonary and vascular pharmacology of sphingosine 1-phosphate

21 January 2018

1 reference

Chemical modulators of sphingosine-1-phosphate receptors as barrier-oriented therapeutic molecules

21 January 2018

1 reference

S1P3 receptors mediate the potent constriction of cerebral arteries by sphingosine-1-phosphate

21 January 2018

1 reference

Sphingosine 1-phosphate and its receptors: an autocrine and paracrine network

21 January 2018

1 reference

Immunomodulator FTY720 Induces eNOS-dependent arterial vasodilatation via the lysophospholipid receptor S1P3.

21 January 2018

1 reference

Activation of the SPHK/S1P signalling pathway is coupled to muscarinic receptor-dependent regulation of peripheral airways

21 January 2018

1 reference

Sphingosine 1-phosphate causes airway hyper-reactivity by rho-mediated myosin phosphatase inactivation

21 January 2018

1 reference

FTY720 immunosuppression impairs effector T cell peripheral homing without affecting induction, expansion, and memory.

21 January 2018

1 reference

Incomplete inhibition of sphingosine 1-phosphate lyase modulates immune system function yet prevents early lethality and non-lymphoid lesions

21 January 2018

1 reference

Novel role of sphingosine kinase 1 as a mediator of neurotrophin-3 action in oligodendrocyte progenitors

21 January 2018

1 reference

Sphingosine-1-Phosphate/Sphingosine Kinase Pathway Is Involved in Mouse Airway Hyperresponsiveness

21 January 2018

1 reference

Fingolimod and sphingosine-1-phosphate--modifiers of lymphocyte migration

21 January 2018

7

1 reference

The immunosuppressant FTY720 down-regulates sphingosine 1-phosphate G-protein-coupled receptors

30 November 2024

16

1 reference

Oral-intravenous crossover study of fingolimod pharmacokinetics, lymphocyte responses and cardiac effects

30 November 2024

21

1 reference

Use of the brain parenchymal fraction to measure whole brain atrophy in relapsing-remitting MS. Multiple Sclerosis Collaborative Research Group

30 November 2024

43

1 reference

FTY720 versus MMF with Cyclosporine in de novo Renal Transplantation: A 1-Year, Randomized Controlled Trial in Europe and Australasia

30 November 2024

47

1 reference

Randomized controlled trial of FTY720 versus MMF in de novo renal transplantation

30 November 2024

48

1 reference

FTY720, a novel immunosuppressant, induces sequestration of circulating mature lymphocytes by acceleration of lymphocyte homing in rats, III. Increase in frequency of CD62L-positive T cells in Peyer's patches by FTY720-induced lymphocyte homing

30 November 2024

53

1 reference

FTY720 preferentially depletes naive T cells from peripheral and lymphoid organs

30 November 2024

54

1 reference

Activation of sphingosine kinase in pheochromocytoma PC12 neuronal cells in response to trophic factors

30 November 2024

67

1 reference

Cultured granule cells and astrocytes from cerebellum differ in metabolizing sphingosine

30 November 2024

68

1 reference

Sphingosine-1-phosphate induces proliferation of astrocytes: regulation by intracellular signalling cascades

30 November 2024

73

1 reference

Sphingosine-1-phosphate induces proliferation and morphological changes of neural progenitor cells

30 November 2024

95

1 reference

Exogenous Sphingosine 1-Phosphate Induces Neurite Retraction Possibly through a Cell Surface Receptor in PC12 Cells

30 November 2024

98

1 reference

Involvement of Sphingosine 1-Phosphate in Nerve Growth Factor-Mediated Neuronal Survival and Differentiation

30 November 2024

100

1 reference

FTY720 sustains and restores neuronal function in the DA rat model of MOG-induced experimental autoimmune encephalomyelitis

30 November 2024

105

1 reference

FTY720: placebo-controlled study of the effect on cardiac rate and rhythm in healthy subjects

30 November 2024

123

1 reference

Sphingosine 1-phosphate regulates inflammation-related genes in human endothelial cells through S1P1 and S1P3

30 November 2024

147

1 reference

30 November 2024

Identifiers

DOI

10.1002/ANA.22426

1 reference

29 July 2017

1 reference